| Literature DB >> 28202460 |
Rick Kapur1,2,3, Michael Kim1,2, Rukhsana Aslam1,2, Mark J McVey1,2,3,4,5,6,7, Arata Tabuchi1, Alice Luo1,4,5,6, Jonathan Liu1,2, Yuan Li1,2,8, Shanjeevan Shanmugabhavananthan1,2, Edwin R Speck1,2, Anne Zufferey1,2, George Yousef9, Haibo Zhang1,4,5,6, Matthew T Rondina10,11,12, Andrew S Weyrich13, Leendert Porcelijn14, Wolfgang M Kuebler1,15,6,16,17, Arthur S Slutsky1,18, John W Semple1,2,3,19,5,20,21.
Abstract
Transfusion-related acute lung injury (TRALI) is the leading cause of transfusion-related fatalities and is characterized by acute respiratory distress following blood transfusion. Donor antibodies are frequently involved; however, the pathogenesis and protective mechanisms in the recipient are poorly understood, and specific therapies are lacking. Using newly developed murine TRALI models based on injection of anti-major histocompatibility complex class I antibodies, we found CD4+CD25+FoxP3+ T regulatory cells (Tregs) and CD11c+ dendritic cells (DCs) to be critical effectors that protect against TRALI. Treg or DC depletion in vivo resulted in aggravated antibody-mediated acute lung injury within 90 minutes with 60% mortality upon DC depletion. In addition, resistance to antibody-mediated TRALI was associated with increased interleukin-10 (IL-10) levels, and IL-10 levels were found to be decreased in mice suffering from TRALI. Importantly, IL-10 injection completely prevented and rescued the development of TRALI in mice and may prove to be a promising new therapeutic approach for alleviating lung injury in this serious complication of transfusion.Entities:
Mesh：
Substances：
Year: 2017 PMID： 28202460 PMCID： PMC5418638 DOI： 10.1182/blood-2016-12-758185
Source DB: PubMed Journal: Blood ISSN： 0006-4971 Impact factor: 22.113